ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1773

Worse Maternal and Fetal Outcomes Among Hospitalized U.S. Pregnant Women with Systemic Lupus Erythematosus (SLE) and Rheumatoid Arthritis (RA)

Christine Anastasiou1, Laura Trupin1, Patricia Katz2, Zara Izadi3, Milena Gianfrancesco1, Gabriela Schmajuk4 and Jinoos Yazdany5, 1University of California, San Francisco, San Francisco, CA, 2University of California, San Francisco, Novato, CA, 3University of California San Francisco, San Francisco, CA, 4University of California, San Francisco, Atherton, CA, 5UCSF, San Francisco, CA

Meeting: ACR Convergence 2020

Keywords: pregnancy, rheumatoid arthritis, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 9, 2020

Title: Reproductive Issues in Rheumatic Disorders Poster

Session Type: Poster Session D

Session Time: 9:00AM-11:00AM

Background/Purpose: Prior studies suggest women with SLE and RA may have higher age-adjusted risk of adverse pregnancy outcomes. We evaluated maternal and fetal complications and racial/ethnic disparities among pregnant women with SLE and RA using a national sample of hospital admissions.

Methods: We used the National Inpatient Sample (NIS), which after weighting provides annual estimates for more than 35 million community hospitalizations in the US. Analysis was limited to pregnant women without missing relevant variables hospitalized in 2016 and 2017. Admissions with SLE and RA were captured in ICD-10-CM codes (M32.1x, M32.8, M32.9 and M05, M06.0, M06.2, M06.8, M06.9, M08.0 respectively). We compared the proportion of discharge outcomes with maternal death, intrauterine fetal demise (IUFD), preeclampsia/eclampsia, premature rupture of membranes (PROM), and placental complications (placental disorders, placenta previa, or abruptio placentae) among patients with SLE, RA, and neither condition using chi-squared tests. We used Poisson regression to model outcomes as a function of disease, including age, race/ethnicity, insurance, and income level in the ZIP Code of residence as covariates. To evaluate racial/ethnic disparities across disease groups, we included an interaction term for race/ethnicity and disease (SLE, RA, neither) if the interaction was significant in the model. Weighted population estimates are presented, except if otherwise specified. All analyses accounted for the complex sampling design of the NIS.

Results: An estimated 11,100 (0.15%) community hospital admissions for pregnant women with SLE, 10,065 (0.13%) with RA, and 7,612,897 for women with neither condition occurred in the U.S. in 2016 and 2017.  Maternal death was a rare event, accounting for less than 10 observations for admissions with either SLE or RA, and approximately 0.01% of general pregnancy related admissions. Admissions with a diagnosis of IUFD, preeclampsia/eclampsia, and placental complications were more likely among patients with SLE than the general pregnant population (p< 0.05) (Table 1). Similarly, admissions for patients with RA were more likely to have a diagnosis of preeclampsia/eclampsia, PROM, and placental complications compared to the general pregnant population (p< 0.05). The risk of IUFD and preeclampsia/eclampsia was higher among Blacks compared to whites (p< 0.05) both among the general pregnant population and those with SLE, but not among those with RA (Table 2).

Conclusion: Pregnant patients with SLE and RA have worse maternal and fetal outcomes including increased risk of intrauterine fetal demise, preeclampsia/eclampsia, PROM, or placental complications compared to other hospitalized pregnant women. Admitted pregnant Black patients with SLE, like those in the general population, continue to be at higher risk of poor maternal and fetal outcomes compared to whites. In contrast, there was no significant difference in the risk of analyzed maternal and fetal complications for Black compared to white RA patients. Women with SLE and RA continue to be at increased risk of pregnancy complications suggesting that additional obstetric research and interventions are indicated to improve outcomes in these patients.

IUFD = intrauterine fetal demise; PROM = premature rupture of membranes; placental complications include ICD-10-CM codes for placental disorders, placenta previa, or abruptio placentae. Percent of discharges based on marginal predictions from adjusted Poisson model. RR= adjusted relative risk obtained from Poisson model including age, race, income quartile in ZIP Code of residence, insurance as covariates. Models for IUFD and preeclampsia/eclampsia also include an interaction term for race/ethnicity and disease. Ref = reference group. *Signifies statistical significance, p < 0.05. n weighted based on NIS guidelines to generate national estimates.

IUFD = intrauterine fetal demise; PROM = premature rupture of membranes; placental complications include ICD-10-CM codes for placental disorders, placenta previa, or abruptio placentae. RR= adjusted relative risk obtained from Poisson model including age, race, income quartile in ZIP Code of residence, insurance as covariates, and an interaction term for race/ethnicity and disease. *Signifies statistical significance, p < 0.05.


Disclosure: C. Anastasiou, None; L. Trupin, None; P. Katz, None; Z. Izadi, None; M. Gianfrancesco, None; G. Schmajuk, None; J. Yazdany, Eli Lilly, 5, Astra Zeneca, 5.

To cite this abstract in AMA style:

Anastasiou C, Trupin L, Katz P, Izadi Z, Gianfrancesco M, Schmajuk G, Yazdany J. Worse Maternal and Fetal Outcomes Among Hospitalized U.S. Pregnant Women with Systemic Lupus Erythematosus (SLE) and Rheumatoid Arthritis (RA) [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/worse-maternal-and-fetal-outcomes-among-hospitalized-u-s-pregnant-women-with-systemic-lupus-erythematosus-sle-and-rheumatoid-arthritis-ra/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/worse-maternal-and-fetal-outcomes-among-hospitalized-u-s-pregnant-women-with-systemic-lupus-erythematosus-sle-and-rheumatoid-arthritis-ra/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology